<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01855841</url>
  </required_header>
  <id_info>
    <org_study_id>Hemin_AP</org_study_id>
    <nct_id>NCT01855841</nct_id>
  </id_info>
  <brief_title>Hemin to Prevent Post-ERCP (Endoscopic Retrograde Cholangiopancreatography) Acute Pancreatitis</brief_title>
  <official_title>Prevention of Post-ERCP Acute Pancreatitis by Heme-oxygenase Activation Through the Administration of Hemin : a Prospective, Randomized Double Blind Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasme University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasme University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ERCP (endoscopic retrograde cholangiopancreatography) has been largely demonstrated to be&#xD;
      effective in multiple bilio-pancreatic indications. However, one of the feared complication&#xD;
      of this technique is acute pancreatitis, which happens in 5 to 25% of cases. Some patient&#xD;
      groups have been demonstrated to present a higher risk linked to individual factors or to the&#xD;
      procedure. Some interventions (endoscopic or pharmacologic) have been evaluated to reduce the&#xD;
      incidence of this complication but each has his own inconvenient. Recently, the activation of&#xD;
      heme oxygenase (HO) by intraperitoneal administration of hemin has been demonstrated to be&#xD;
      effective in prevention and treatment of acute pancreatitis mice models. This protective&#xD;
      effect has been associated to intrapancreatic HO-1 positive macrophage recruitment activated&#xD;
      by hemin. The investigators thus propose to conduct a prospective randomized double blind&#xD;
      controlled trial to demonstrate a protective effect of hemin administration against post-ERCP&#xD;
      acute pancreatitis in high risk patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients for who a pancreatic stent placement is indicated will be excluded from the study.&#xD;
&#xD;
      The aims of this study are: 1) to study in a pathophysiologic point of view the activation of&#xD;
      HO-1 by hemin in human and its protective effect in post-ERCP acute pancreatitis incidence.&#xD;
      2) to use the human situation of post-ERCP acute pancreatitis as early pancreatitis model to&#xD;
      study the administration of hemin as treatment of acute pancreatitis in general.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2012</start_date>
  <completion_date type="Actual">June 2021</completion_date>
  <primary_completion_date type="Actual">June 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of post-ERCP acute pancreatitis</measure>
    <time_frame>at day 1 post-ERCP</time_frame>
    <description>Post-ERCP acute pancreatitis is defined by an abdominal pain compatible with pancreatitis and the elevation of seric lipases more than 3 times the upper limit of normal on days 1 post-ERCP.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>severity of post-ERCP acute pancreatitis</measure>
    <time_frame>during the hospital stay (up to 2 months)</time_frame>
    <description>If post-ERCP acute pancreatitis happens, all parameters of severity will be recorded (clinical, biological, intra-abdominal collections seen on abdominal scanner/magnetic resonance, organ failure, need for ICU hospitalization, need for further treatment: surgery/endoscopy/radiological drainage?)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of stay</measure>
    <time_frame>during the hospitalization (up to 2 months)</time_frame>
    <description>the length of stay in the hospital will be recorded. if a complication occurs (post-ERCP acute pancreatitis or other, it will be recorded)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety of hemin administration</measure>
    <time_frame>within 7 days</time_frame>
    <description>Few side effects of hemin are known (headache, superficial thrombophlebitis in the perfused vein); they will be recorded as well as other unexplained clinico-biological events</description>
  </secondary_outcome>
  <other_outcome>
    <measure>number of patients with post-ERCP acute pancreatitis and adverse event at interim analysis</measure>
    <time_frame>after 100 patients</time_frame>
    <description>After having randomized 50 patients by arm, an interim analysis will be conducted to evaluate the safety (superficial venous thrombophlebitis, headache, unexpected adverse events)and need to complete the study (depending on the results on post-ERCP acute pancreatitis incidence)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">284</enrollment>
  <condition>Post-ERCP Acute Pancreatitis</condition>
  <arm_group>
    <arm_group_label>Hemin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A peripheral perfusion of 4mg/kg of hemin (Normosang) diluted in 100mL NaCL (sodium chloride) 0.9% will be administered in 30-60minutes as soon as possible after the end of the ERCP, followed by 100mL of NacL 0.9% to flush the vein</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The same amount of NaCl 0.9% (100 ML followed by a flushing perfusion of 100mL) will be perfused to the patient as soon as possible after the end of the ERCP</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hemin</intervention_name>
    <description>A single perfusion of 4mg/kg hemin diluted in 100mL of NaCl 0.9% administered as soon as possible after the end of the ERCP followed by 100mL of NaCL 0.9% to flush the vein</description>
    <arm_group_label>Hemin</arm_group_label>
    <other_name>Haemin</other_name>
    <other_name>Normosang</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>A single perfusion of 100mL of NaCl 0.9% administered as soon as possible after the end of the ERCP followed by 100mL of NaCL 0.9% to flush the vein</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: one or more factors of &gt;10% post-ERCP acute pancreatitis risk:&#xD;
&#xD;
          -  former episode of acute pancreatitis&#xD;
&#xD;
          -  former episode of post-ERCP acute pancreatitis&#xD;
&#xD;
          -  normal bilirubin level&#xD;
&#xD;
          -  main pancreatic duct injection&#xD;
&#xD;
          -  endoscopic biliary sphincteroplasty (balloon dilation of biliary sphincter)&#xD;
&#xD;
          -  precut papillotomy&#xD;
&#xD;
          -  pancreatic sphincterotomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patient for whom a pancreatic stent is inserted (Sphincter of Oddi dysfunction,&#xD;
             ampullectomy)&#xD;
&#xD;
          -  ongoing acute pancreatitis&#xD;
&#xD;
          -  chronic pancreatitis (Cremer classification &gt;=2)&#xD;
&#xD;
          -  age &lt; 18 y/o&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  hemin allergy&#xD;
&#xD;
          -  severe renal failure (MDRD&lt;30ml/min/1.73m2)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnaud Lemmers, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasme Hospital, Université libre de Bruxelles (ULB), Brussels, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacques Devière, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Erasme Hospital, Université Libre de Bruxelles (ULB), Brussels, Blegium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Brugmann</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasme Hospital, Université Libre de Bruxelles (ULB)</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Jolimont-Lobbes</name>
      <address>
        <city>Haine-St-Paul</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Ambroise Paré</name>
      <address>
        <city>Mons</city>
        <zip>7000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ISPPC CHU Vésale</name>
      <address>
        <city>Montigny Le tilleul</city>
        <zip>6110</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Taiwan</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 8, 2013</study_first_submitted>
  <study_first_submitted_qc>May 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2013</study_first_posted>
  <last_update_submitted>July 5, 2021</last_update_submitted>
  <last_update_submitted_qc>July 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasme University Hospital</investigator_affiliation>
    <investigator_full_name>Lemmers Arnaud</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>ERCP</keyword>
  <keyword>virgin papilla</keyword>
  <keyword>risk of post-ERCP acute pancreatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

